NCT00071409 - Safety and Efficacy of INGAP-Peptide in Patients With Type 1 Diabetes | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

May 31, 2004

Study Completion Date

May 31, 2004

Conditions

Diabetes Mellitus, Insulin-Dependent

Interventions

DRUG

INGAP-Peptide

1.5 mL, once daily, self-administered SC injection for 90 days

DRUG

INGAP-Peptide

1.5 mL, once daily, self-administered SC injection for 90 days

DRUG

placebo

1.5 mL, once daily, self-administered SC injection for 90 days

Trial Locations (10)

MedStar Clinical Research Center, Washington D.C.

UNC Diabetes Care Center, Durham

Mercury Street Medical, Butte

Springfield Diabetes and Endocrine Center, Springfield

University of Texas Health Science Center - Texas Diabetes Institute, San Antonio

DGD Research Associates, San Antonio

VA Hospital UCSD, San Diego

Radiant Research, Irvine

Diablo Clinical Research, Walnut Creek

Clinical Research Institute of Southern Oregon, Medford